# David Langleben

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5503984/publications.pdf

Version: 2024-02-01

| 83 | 15,101 | 117453 | 74018 |
|---|---|---|---|
| papers | citations | 34 h-index | 75 g-index |

| 84 | 84 | 84 | 8172 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The Role of Thyroid Disorders, Obesity, Diabetes Mellitus and Estrogen Exposure as Potential Modifiers for Pulmonary Hypertension. Journal of Clinical Medicine, 2022, 11, 921. | 1.0 | 5 |
| 2 | Oral anticoagulants (NOAC and VKA) in chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2022, 41, 716-721. | 0.3 | 28 |
| 3 | Pulmonary capillary recruitment and distention in mammalian lungs: species similarities.. European Respiratory Review, 2022, 31, . | 3.0 | 2 |
| 4 | Decreased bone morphogenetic protein type II receptor and BMP-related signalling moleculesâ€™ expression in aquaporin 1-silenced human pulmonary microvascular endothelial cells. Hellenic Journal of Cardiology, 2021, 62, 84-86. | 0.4 | 1 |
| 5 | Riociguat: Clinical research and evolving role in therapy. British Journal of Clinical Pharmacology, 2021, 87, 2645-2662. | 1.1 | 18 |
| 6 | Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 178, 106220. | 1.3 | 23 |
| 7 | Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. Respiratory Medicine, 2021, 177, 106241. | 1.3 | 13 |
| 8 | Selexipag Therapy for Raynaud Phenomenon-induced Severe Digital Ischemia in Intravenous Epoprostenol Responders With Connective Tissue Disease. Journal of Rheumatology, 2021, 48, 616-617. | 1.0 | 2 |
| 9 | Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 573-584. | 5.2 | 85 |
| 10 | Effect of riociguat on right ventricular function in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Journal of Heart and Lung Transplantation, 2021, 40, 1172-1180. | 0.3 | 9 |
| 11 | Results of an Expert Consensus Survey on the Treatment of Pulmonary Arterial Hypertension With Oral Prostacyclin Pathway Agents. Chest, 2020, 157, 955-965. | 0.4 | 26 |
| 12 | Impact of saline loading at cardiac catheterization on the classification and management of patients evaluated for pulmonary hypertension. International Journal of Cardiology, 2020, 306, 181-186. | 0.8 | 3 |
| 13 | Canadian Cardiovascular Society/Canadian Thoracic Society Position Statement on Pulmonary Hypertension. Canadian Journal of Cardiology, 2020, 36, 977-992. | 0.8 | 29 |
| 14 | Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies). Pulmonary Circulation, 2020, 10, 1-10. | 0.8 | 4 |
| 15 | Knockdown of bone morphogenetic protein type II receptor leads to decreased aquaporin 1 expression and function in human pulmonary microvascular endothelial cells. Canadian Journal of Physiology and Pharmacology, 2020, 98, 834-839. | 0.7 | 4 |
| 16 | Assessment of the REPLACE study composite endpoint in riociguatâ€treated patients in the PATENT study. Pulmonary Circulation, 2020, 10, 1-8. | 0.8 | 4 |
| 17 | Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. International Journal of Cardiology, 2020, 317, 188-192. | 0.8 | 5 |
| 18 | Pulmonary capillary surface area in supine exercising humans: demonstration of vascular recruitment. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2019, 317, L361-L368. | 1.3 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Pathophysiology of the right ventricle andÂof the pulmonary circulation in pulmonary hypertension: an update. European Respiratory Journal, 2019, 53, 1801900. | 3.1 | 315 |
| 20 | Pulmonary capillary recruitment in exercise and pulmonary hypertension. European Respiratory Journal, 2018, 51, 1702559. | 3.1 | 1 |
| 21 | REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. Journal of Heart and Lung Transplantation, 2018, 37, 513-519. | 0.3 | 29 |
| 22 | Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension. Chest, 2017, 151, 468-480. | 0.4 | 79 |
| 23 | Comparison of hemodynamic parameters in treatment-naÃ¯ve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2017, 36, 509-519. | 0.3 | 22 |
| 24 | Molecular imaging of the human pulmonary vascular endothelium in pulmonary hypertension: a phase II safety and proof of principle trial. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1136-1144. | 3.3 | 11 |
| 25 | Vasodilator responsiveness in idiopathic pulmonary arterial hypertension: identifying a distinct phenotype with distinct physiology and distinct prognosis. Pulmonary Circulation, 2017, 7, 588-597. | 0.8 | 3 |
| 26 | Right ventricular STâ€elevation myocardial infarction as a cause of death in idiopathic pulmonary arterial hypertension. Pulmonary Circulation, 2017, 7, 555-558. | 0.8 | 0 |
| 27 | Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. Respiratory Medicine, 2017, 122, S18-S22. | 1.3 | 15 |
| 28 | RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors. European Respiratory Journal, 2017, 50, 1602425. | 3.1 | 113 |
| 29 | Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial. Lancet Respiratory Medicine,the, 2016, 4, 361-371. | 5.2 | 97 |
| 30 | Pregnancy as a Possible Trigger for Heritable Pulmonary Arterial Hypertension. Pulmonary Circulation, 2016, 6, 381-383. | 0.8 | 9 |
| 31 | Combination Therapy for Pulmonary Arterial Hypertension: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2016, 32, 1520-1530. | 0.8 | 50 |
| 32 | Evaluation of the Microstatâ„¢ sublingual PCO2 monitor in ambulatory patients. Journal of Clinical Monitoring and Computing, 2016, 30, 77-80. | 0.7 | 3 |
| 33 | Acute Vasodilator Responsiveness and Microvascular Recruitment in Idiopathic Pulmonary Arterial Hypertension. Annals of Internal Medicine, 2015, 162, 154-156. | 2.0 | 20 |
| 34 | Leaflet Area as a Determinant of Tricuspid Regurgitation Severity in Patients With Pulmonary Hypertension. Circulation: Cardiovascular Imaging, 2015, 8, . | 1.3 | 45 |
| 35 | Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2). European Respiratory Journal, 2015, 45, 1303-1313. | 3.1 | 174 |
| 36 | Use of clinically relevant responder threshold criteria to evaluate the response to treatment in the Phase III PATENT-1 study. Journal of Heart and Lung Transplantation, 2015, 34, 338-347. | 0.3 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension. Circulation Research, 2015, 117, 645-654. | 2.0 | 120 |
| 38 | Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1345-1354. | 2.5 | 82 |
| 39 | The Use of Antidepressants and the Risk of Idiopathic Pulmonary Arterial Hypertension. Canadian Journal of Cardiology, 2014, 30, 1633-1639. | 0.8 | 15 |
| 40 | Usefulness of Right Ventricular Dysfunction to Predict New-Onset Atrial Fibrillation Following Coronary Artery Bypass Grafting. American Journal of Cardiology, 2014, 113, 913-918. | 0.7 | 18 |
| 41 | EPITOME-2: An open-label study assessing the transition to a new formulation of intravenous epoprostenol in patients with pulmonary arterial hypertension. American Heart Journal, 2014, 167, 210-217. | 1.2 | 59 |
| 42 | Effects of vascular endothelial growth factor on endothelin-1 production by human lung microvascular endothelial cells in vitro. Life Sciences, 2014, 118, 191-194. | 2.0 | 18 |
| 43 | Pulmonary Capillary Hemangiomatosis. Chest, 2014, 145, 197-199. | 0.4 | 16 |
| 44 | From the Echo Bed to the Pulmonary Vascular Bed. Chest, 2014, 146, 876-878. | 0.4 | 0 |
| 45 | Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 330-340. | 13.9 | 1,120 |
| 46 | Definitions and Diagnosis of Pulmonary Hypertension. Journal of the American College of Cardiology, 2013, 62, D42-D50. | 1.2 | 1,467 |
| 47 | Step climbing capacity in patients with pulmonary hypertension. Clinical Research in Cardiology, 2013, 102, 51-61. | 1.5 | 13 |
| 48 | Hemodynamic Stability After Transitioning Between Endothelin Receptor Antagonists in Patients With Pulmonary Arterial Hypertension. Canadian Journal of Cardiology, 2013, 29, 672-677. | 0.8 | 9 |
| 49 | ALK2 and BMPR2 knockdown and endothelin-1 production by pulmonary microvascular endothelial cells. Microvascular Research, 2013, 85, 46-53. | 1.1 | 23 |
| 50 | Pulmonary Arterial Hypertension in the Elderly-Clinical Characteristics and Long-Term Survival. Lung, 2012, 190, 645-649. | 1.4 | 22 |
| 51 | Prevalence and Impact of Coronary Artery Disease in Patients With Pulmonary Arterial Hypertension. American Journal of Cardiology, 2011, 108, 460-464. | 0.7 | 26 |
| 52 | Metabolic and Clearance Function at the Pulmonary Microvascular Endothelial Surface in Pulmonary Hypertension. , 2011, , 105-115. | | 1 |
| 53 | Systemic Sclerosis and Early-Onset Pulmonary Hypertension. Chest, 2010, 138, 238-239. | 0.4 | 0 |
| 54 | Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells. Microvascular Research, 2010, 80, 349-354. | 1.1 | 42 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | What is the Current State of Stem Cell Research in PAH?. Advances in Pulmonary Hypertension, 2010, 9, 145-145. | 0.1 | 0 |
| 56 | Effects of bone morphogenic proteins and transforming growth factor-beta on In-vitro production of endothelin-1 by human pulmonary microvascular endothelial cells. Vascular Pharmacology, 2009, 50, 45-50. | 1.0 | 22 |
| 57 | Updated Clinical Classification of Pulmonary Hypertension. Journal of the American College of Cardiology, 2009, 54, S43-S54. | 1.2 | 1,919 |
| 58 | Near-Term Novel Therapies for PAH. Advances in Pulmonary Hypertension, 2009, 8, 17-20. | 0.1 | 0 |
| 59 | Pulmonary capillary endothelial metabolic dysfunction: Severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic pulmonary arterial hypertension. Arthritis and Rheumatism, 2008, 58, 1156-1164. | 6.7 | 40 |
| 60 | Endothelin and Its Blockade in Pulmonary Arterial Hypertension. , 2008, , 283-303. | | 0 |
| 61 | Endothelin Receptor Antagonists in the Treatment of Pulmonary Arterial Hypertension. Clinics in Chest Medicine, 2007, 28, 117-125. | 0.8 | 36 |
| 62 | Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan. Journal of the American College of Cardiology, 2006, 47, 2049-2056. | 1.2 | 462 |
| 63 | Temporal trends and drug exposures in pulmonary hypertension: An American experience. American Heart Journal, 2006, 152, 521-526. | 1.2 | 78 |
| 64 | Etiology-Specific Endothelin-1 Clearance in Human Precapillary Pulmonary Hypertension. Chest, 2006, 129, 689-695. | 0.4 | 55 |
| 65 | Clinical Challenges in Pulmonary Hypertension. Chest, 2005, 128, 622S-628S. | 0.4 | 23 |
| 66 | Canadian Cardiovascular Society and Canadian Thoracic Society Position Statement on Pulmonary Arterial Hypertension. Canadian Respiratory Journal, 2005, 12, 303-315. | 0.8 | 5 |
| 67 | Cardiac Catheterization in Pulmonary Arterial Hypertension: An Updated Guide to Proper Use. Advances in Pulmonary Hypertension, 2005, 4, 15-25. | 0.1 | 14 |
| 68 | Canadian Cardiovascular Society and Canadian Thoracic Society position statement on pulmonary arterial hypertension. Canadian Journal of Cardiology, 2005, 21, 909-14. | 0.8 | 4 |
| 69 | Sitaxsentan Therapy for Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 441-447. | 2.5 | 674 |
| 70 | Sustained Symptomatic, Functional, and Hemodynamic Benefit With the Selective Endothelin-A Receptor Antagonist, Sitaxsentan, in Patients With Pulmonary Arterial Hypertension. Chest, 2004, 126, 1377-1381. | 0.4 | 58 |
| 71 | Clinical classification of pulmonary hypertension. Journal of the American College of Cardiology, 2004, 43, S5-S12. | 1.2 | 1,542 |
| 72 | STRIDE 1: Effects of the Selective ETA Receptor Antagonist, Sitaxsentan Sodium, in a Patient Population with Pulmonary Arterial Hypertension that meets Traditional Inclusion Criteria of Previous Pulmonary Arterial Hypertension Trials. Journal of Cardiovascular Pharmacology, 2004, 44, S80-S84. | 0.8 | 54 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. American Heart Journal, 2002, 143, 4A-10A. | 1.2 | 68 |
| 74 | Pulmonary capillary endothelial dysfunction in early systemic sclerosis. Arthritis and Rheumatism, 2001, 44, 902-911. | 6.7 | 43 |
| 75 | Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease. Annals of Internal Medicine, 2000, 132, 425. | 2.0 | 905 |
| 76 | Pulmonary Capillary Endothelium-Bound Angiotensin-Converting Enzyme Activity in Acute Lung Injury. Circulation, 2000, 102, 2011-2018. | 1.6 | 153 |
| 77 | Continuous Infusion of Epoprostenol Improves the Net Balance Between Pulmonary Endothelin-1 Clearance and Release in Primary Pulmonary Hypertension. Circulation, 1999, 99, 3266-3271. | 1.6 | 70 |
| 78 | Pulmonary Capillary Endothelium-Bound Angiotensin-Converting Enzyme Activity in Humans. Circulation, 1999, 99, 1593-1599. | 1.6 | 62 |
| 79 | A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary Hypertension. New England Journal of Medicine, 1996, 334, 296-301. | 13.9 | 2,529 |
| 80 | Short-term Pulmonary Vasodilation With<scp>l</scp>-Arginine in Pulmonary Hypertension. Circulation, 1995, 92, 1539-1545. | 1.6 | 149 |
| 81 | Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension. New England Journal of Medicine, 1993, 328, 1732-1739. | 13.9 | 1,698 |
| 82 | Interspecies Variation in the Cellular Phase of Blood Fibrinolytic Activity. Experimental Biology and Medicine, 1991, 196, 270-272. | 1.1 | 2 |
| 83 | Familial Pulmonary Capillary Hemangiomatosis Resulting in Primary Pulmonary Hypertension. Annals of Internal Medicine, 1988, 109, 106. | 2.0 | 117 |